Black Diamond Therapeutics, BDTX-1535
Black Diamond Therapeutics Gains On Positive Phase 2 Data For BDTX-1535 In Patients With NSCLC
(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or refractory non-small cell lung cancer also known as NSCLC, caused by epidermal growth factor receptor or EGFR mutations. Following this news, the stock is up 40% in the pre-market trade.
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging ...
Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its ...
Emma Coronel, the wife of El Chapo, walked the runway yesterday, Sunday, September 22, in Milan in a wedding dress for April ...
Black Diamond’s Traverse 3 poles are simplicity refined. The Traverse 3 is a 125cm touring pole in 3 sections, a magical ...
Black Diamond Therapeutics (BDTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating ...
A rare diamond necklace with possible links to former French queen consort Marie Antoinette is to be auctioned in November ...
Panick Entertainment has launched new titles on the crowdfunding platform Zoop with T.A.M.A, Savager and Black Diamond.
Goreville Football will no longer participate in the Black Diamond Conference. This comes after a vote by the BDC that was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback